Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Christina Aquilante to Humans

This is a "connection" page, showing publications Christina Aquilante has written about Humans.

 
Connection Strength
  
 
 
0.638
  
  1. Anderson HD, Thant TM, Kao DP, Crooks KR, Mendola ND, Aquilante CL. Pharmacogenetic testing among patients with depression in a US managed care population. Clin Transl Sci. 2022 07; 15(7):1644-1653.
    View in: PubMed
    Score: 0.023
  2. Martin JL, Lee YM, Corbin LW, Colson R, Aquilante CL. Patients' perspectives of a pharmacist-provided clinical pharmacogenomics service. Pharmacogenomics. 2022 06; 23(8):463-474.
    View in: PubMed
    Score: 0.023
  3. Oreschak K, Saba LM, Rafaels N, Ambardekar AV, Deininger KM, PageII R, Lindenfeld J, Aquilante CL. Variants in mycophenolate and CMV antiviral drug pharmacokinetic and pharmacodynamic genes and leukopenia in heart transplant recipients. J Heart Lung Transplant. 2021 09; 40(9):917-925.
    View in: PubMed
    Score: 0.021
  4. Liko I, Lee YM, Stutzman DL, Blackmer AB, Deininger KM, Reynolds AM, Aquilante CL. Providers'?perspectives on the clinical utility of pharmacogenomic testing in pediatric patients. Pharmacogenomics. 2021 04; 22(5):263-274.
    View in: PubMed
    Score: 0.021
  5. Deininger KM, Tsunoda SM, Hirsch JD, Anderson H, Lee YM, McIlvennan CK, Page RL, Tran JN, Aquilante CL. National survey of physicians' perspectives on pharmacogenetic testing in solid organ transplantation. Clin Transplant. 2020 10; 34(10):e14037.
    View in: PubMed
    Score: 0.020
  6. Nagy M, Lynch M, Kamal S, Mohamed S, Hadad A, Abouelnaga S, Aquilante CL. Assessment of healthcare professionals'?knowledge, attitudes, and perceived challenges of clinical pharmacogenetic testing in Egypt. Per Med. 2020 07 01; 17(4):251-260.
    View in: PubMed
    Score: 0.020
  7. Anderson HD, Crooks KR, Kao DP, Aquilante CL. The landscape of pharmacogenetic testing in a US managed care population. Genet Med. 2020 07; 22(7):1247-1253.
    View in: PubMed
    Score: 0.020
  8. Oreschak K, Wolfel EE, Saba LM, Ambardekar AV, Lindenfeld J, Aquilante CL. Relationship between nocturnal blood pressure patterns and end organ damage and diastolic dysfunction in heart transplant recipients. Clin Transplant. 2020 05; 34(5):e13842.
    View in: PubMed
    Score: 0.020
  9. Aquilante CL, Kao DP, Trinkley KE, Lin CT, Crooks KR, Hearst EC, Hess SJ, Kudron EL, Lee YM, Liko I, Lowery J, Mathias RA, Monte AA, Rafaels N, Rioth MJ, Roberts ER, Taylor MR, Williamson C, Barnes KC. Clinical implementation of pharmacogenomics via a health system-wide research biobank: the University of Colorado experience. Pharmacogenomics. 2020 04; 21(6):375-386.
    View in: PubMed
    Score: 0.019
  10. Deininger KM, Tran JN, Tsunoda SM, Young GK, Lee YM, Anderson HD, Page Ii RL, Hirsch JD, Aquilante CL. Stakeholder perspectives of the clinical utility of pharmacogenomic testing in solid organ transplantation. Pharmacogenomics. 2019 12; 20(18):1291-1302.
    View in: PubMed
    Score: 0.019
  11. Deininger KM, Page RL, Lee YM, Kauffman YS, Johnson SG, Oreschak K, Aquilante CL. Non-interventional cardiologists' perspectives on the role of pharmacogenomic testing in cardiovascular medicine. Per Med. 2019 03; 16(2):123-132.
    View in: PubMed
    Score: 0.018
  12. Cobretti MR, Page RL, Linnebur SA, Deininger KM, Ambardekar AV, Lindenfeld J, Aquilante CL. Medication regimen complexity in ambulatory older adults with heart failure. Clin Interv Aging. 2017; 12:679-686.
    View in: PubMed
    Score: 0.016
  13. Bryant BM, Libby AM, Metz KR, Page RL, Ambardekar AV, Lindenfeld J, Aquilante CL. Evaluating Patient-Level Medication Regimen Complexity Over Time in Heart Transplant Recipients. Ann Pharmacother. 2016 11; 50(11):926-934.
    View in: PubMed
    Score: 0.015
  14. Deininger KM, Vu A, Page RL, Ambardekar AV, Lindenfeld J, Aquilante CL. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients. Clin Transplant. 2016 09; 30(9):1074-81.
    View in: PubMed
    Score: 0.015
  15. Vu A, Kosmiski LA, Beitelshees AL, Prigeon R, Sidhom MS, Bredbeck B, Predhomme J, Deininger KM, Aquilante CL. Pharmacodynamic Effects of Low-Dose Pioglitazone in Patients with the Metabolic Syndrome without Diabetes Mellitus. Pharmacotherapy. 2016 Mar; 36(3):252-62.
    View in: PubMed
    Score: 0.015
  16. Aquilante CL, Page RL, Vu A, Roscoe N, Wolfel EE, Lindenfeld JA. Comparison of office, home, and ambulatory blood pressure in heart transplant recipients. J Card Fail. 2014 Aug; 20(8):602-10.
    View in: PubMed
    Score: 0.013
  17. Aquilante CL, Niemi M, Gong L, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenet Genomics. 2013 Dec; 23(12):721-8.
    View in: PubMed
    Score: 0.013
  18. Aquilante CL, Wempe MF, Spencer SH, Kosmiski LA, Predhomme JA, Sidhom MS. Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers. Pharmacotherapy. 2013 Sep; 33(9):1000-7.
    View in: PubMed
    Score: 0.012
  19. Aquilante CL, Wempe MF, Sidhom MS, Kosmiski LA, Predhomme JA. Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers. Eur J Clin Pharmacol. 2013 Jul; 69(7):1401-9.
    View in: PubMed
    Score: 0.012
  20. Aquilante CL, Kosmiski LA, Bourne DW, Bushman LR, Daily EB, Hammond KP, Hopley CW, Kadam RS, Kanack AT, Kompella UB, Le M, Predhomme JA, Rower JE, Sidhom MS. Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Br J Clin Pharmacol. 2013 Jan; 75(1):217-26.
    View in: PubMed
    Score: 0.012
  21. Kadam R, Bourne D, Kompella U, Aquilante C. Effect of Cytochrome P450 2C8*3 on the Population Pharmacokinetics of Pioglitazone in Healthy Caucasian Volunteers. Biol Pharm Bull. 2013; 36(2):245-51.
    View in: PubMed
    Score: 0.012
  22. Aquilante CL, Kiser JJ, Anderson PL, Christians U, Kosmiski LA, Daily EB, Hoffman KL, Hopley CW, Predhomme JA, Schniedewind B, Sidhom MS. Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin. J Clin Pharmacol. 2012 Nov; 52(11):1725-38.
    View in: PubMed
    Score: 0.011
  23. Rower JE, Bushman LR, Hammond KP, Kadam RS, Aquilante CL. Validation of an LC/MS method for the determination of gemfibrozil in human plasma and its application to a pharmacokinetic study. Biomed Chromatogr. 2010 Dec; 24(12):1300-8.
    View in: PubMed
    Score: 0.010
  24. Aquilante CL, Kosmiski LA, Zineh I, Rome LC, Knutsen SD. Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome. Pharmacotherapy. 2010 Mar; 30(3):236-47.
    View in: PubMed
    Score: 0.010
  25. Aquilante CL. Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther. 2010 Mar; 8(3):359-72.
    View in: PubMed
    Score: 0.010
  26. Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009 Sep; 10(9):1489-510.
    View in: PubMed
    Score: 0.009
  27. Aquilante CL, Bushman LR, Knutsen SD, Burt LE, Rome LC, Kosmiski LA. Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers. Hum Genomics. 2008 Sep; 3(1):7-16.
    View in: PubMed
    Score: 0.009
  28. Pacanowski MA, Hopley CW, Aquilante CL. Interindividual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphisms. Expert Opin Drug Metab Toxicol. 2008 May; 4(5):529-44.
    View in: PubMed
    Score: 0.009
  29. Aquilante CL, Kosmiski LA, Knutsen SD, Zineh I. Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults. Metabolism. 2008 Apr; 57(4):494-501.
    View in: PubMed
    Score: 0.009
  30. Aquilante CL, Yarandi HN, Cavallari LH, Andrisin TE, Terra SG, Lewis JF, Hamilton KK, Johnson JA. Beta-adrenergic receptor gene polymorphisms and hemodynamic response to dobutamine during dobutamine stress echocardiography. Pharmacogenomics J. 2008 Dec; 8(6):408-15.
    View in: PubMed
    Score: 0.008
  31. Aquilante CL. Pharmacogenetics of thiazolidinedione therapy. Pharmacogenomics. 2007 Aug; 8(8):917-31.
    View in: PubMed
    Score: 0.008
  32. Aquilante CL, Zhang W, McCollum M. Race, ethnicity, and use of thiazolidinediones among US adults with diabetes. Curr Med Res Opin. 2007 Mar; 23(3):489-94.
    View in: PubMed
    Score: 0.008
  33. Aquilante CL, Beitelshees AL, Zineh I. Correlates of serum matrix metalloproteinase-8 (MMP-8) concentrations in nondiabetic subjects without cardiovascular disease. Clin Chim Acta. 2007 Apr; 379(1-2):48-52.
    View in: PubMed
    Score: 0.008
  34. Aquilante CL, Zineh I, Beitelshees AL, Langaee TY. Common laboratory methods in pharmacogenomics studies. Am J Health Syst Pharm. 2006 Nov 01; 63(21):2101-10.
    View in: PubMed
    Score: 0.008
  35. Aquilante CL, Terra SG, Schofield RS, Pauly DF, Hatton PS, Binkley PF, Johnson JA. Sustained restoration of autonomic balance with long- but not short-acting metoprolol in patients with heart failure. J Card Fail. 2006 Apr; 12(3):171-6.
    View in: PubMed
    Score: 0.007
  36. Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther. 2006 Apr; 79(4):291-302.
    View in: PubMed
    Score: 0.007
  37. Aquilante CL, Humma LM, Yarandi HN, Andrisin TE, Lewis JF, Hamilton KK, Johnson JA. Influence of gender and race on hemodynamic response to dobutamine during dobutamine stress echocardiography. Am J Cardiol. 2004 Aug 15; 94(4):535-8.
    View in: PubMed
    Score: 0.007
  38. Aquilante CL, Lobmeyer MT, Langaee TY, Johnson JA. Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory. Pharmacotherapy. 2004 Jun; 24(6):720-6.
    View in: PubMed
    Score: 0.007
  39. Wiley LK, Shortt JA, Roberts ER, Lowery J, Kudron E, Lin M, Mayer D, Wilson M, Brunetti TM, Chavan S, Phang TL, Pozdeyev N, Lesny J, Wicks SJ, Moore ET, Morgenstern JL, Roff AN, Shalowitz EL, Stewart A, Williams C, Edelmann MN, Hull M, Patton JT, Axell L, Ku L, Lee YM, Jirikowic J, Tanaka A, Todd E, White S, Peterson B, Hearst E, Zane R, Greene CS, Mathias R, Coors M, Taylor M, Ghosh D, Kahn MG, Brooks IM, Aquilante CL, Kao D, Rafaels N, Crooks KR, Hess S, Barnes KC, Gignoux CR. Building a vertically integrated genomic learning health system: The biobank at the Colorado Center for Personalized Medicine. Am J Hum Genet. 2024 Jan 04; 111(1):11-23.
    View in: PubMed
    Score: 0.006
  40. Tuteja S, Salloum RG, Elchynski AL, Smith DM, Rowe E, Blake KV, Limdi NA, Aquilante CL, Bates J, Beitelshees AL, Cipriani A, Duong BQ, Empey PE, Formea CM, Hicks JK, Mroz P, Oslin D, Pasternak AL, Petry N, Ramsey LB, Schlichte A, Swain SM, Ward KM, Wiisanen K, Skaar TC, Van Driest SL, Cavallari LH, Bishop JR. Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy. Clin Transl Sci. 2022 02; 15(2):371-383.
    View in: PubMed
    Score: 0.005
  41. Dawwas GK, Hennessy S, Brensinger CM, Deo R, Bilker WB, Soprano SE, Dhopeshwarkar N, Flory JH, Bloomgarden ZT, Aquilante CL, Kimmel SE, Leonard CE. Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors and Sudden Cardiac Arrest and Ventricular Arrhythmia: Population-Based Cohort Studies. Clin Pharmacol Ther. 2022 01; 111(1):227-242.
    View in: PubMed
    Score: 0.005
  42. Duarte JD, Dalton R, Elchynski AL, Smith DM, Cicali EJ, Lee JC, Duong BQ, Petry NJ, Aquilante CL, Beitelshees AL, Empey PE, Johnson JA, Obeng AO, Pasternak AL, Pratt VM, Ramsey LB, Tuteja S, Van Driest SL, Wiisanen K, Hicks JK, Cavallari LH. Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing. Genet Med. 2021 12; 23(12):2335-2341.
    View in: PubMed
    Score: 0.005
  43. Liko I, Corbin L, Tobin E, Aquilante CL, Lee YM. Implementation of a pharmacist-provided pharmacogenomics service in an executive health program. Am J Health Syst Pharm. 2021 06 07; 78(12):1094-1103.
    View in: PubMed
    Score: 0.005
  44. Lazorwitz A, Aquilante CL, Shortt JA, Sheeder J, Teal S, Gignoux CR. Applicability of ancestral genotyping in pharmacogenomic research with hormonal contraception. Clin Transl Sci. 2021 09; 14(5):1713-1718.
    View in: PubMed
    Score: 0.005
  45. Hicks JK, El Rouby N, Ong HH, Schildcrout JS, Ramsey LB, Shi Y, Anne Tang L, Aquilante CL, Beitelshees AL, Blake KV, Cimino JJ, Davis BH, Empey PE, Kao DP, Lemkin DL, Limdi NA, P Lipori G, Rosenman MB, Skaar TC, Teal E, Tuteja S, Wiley LK, Williams H, Winterstein AG, Van Driest SL, Cavallari LH, Peterson JF. Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems. Clin Pharmacol Ther. 2021 07; 110(1):179-188.
    View in: PubMed
    Score: 0.005
  46. Riordan M, Oreschak K, Peters LL, Aquilante CL, Ambardekar AV. Bariatric Surgery Is Associated With Decreased Calcineurin Inhibitor Time in Therapeutic Range After Heart Transplantation. Transplant Proc. 2021 Mar; 53(2):681-685.
    View in: PubMed
    Score: 0.005
  47. Ramsey LB, Ong HH, Schildcrout JS, Shi Y, Tang LA, Hicks JK, El Rouby N, Cavallari LH, Tuteja S, Aquilante CL, Beitelshees AL, Lemkin DL, Blake KV, Williams H, Cimino JJ, Davis BH, Limdi NA, Empey PE, Horvat CM, Kao DP, Lipori GP, Rosenman MB, Skaar TC, Teal E, Winterstein AG, Owusu Obeng A, Salyakina D, Gupta A, Gruber J, McCafferty-Fernandez J, Bishop JR, Rivers Z, Benner A, Tamraz B, Long-Boyle J, Peterson JF, Van Driest SL. Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients. JAMA Netw Open. 2020 12 01; 3(12):e2029411.
    View in: PubMed
    Score: 0.005
  48. Liko I, Lai E, Griffin RJ, Aquilante CL, Lee YM. Patients' Perspectives on Psychiatric Pharmacogenetic Testing. Pharmacopsychiatry. 2020 Nov; 53(6):256-261.
    View in: PubMed
    Score: 0.005
  49. Lazorwitz A, Dindinger E, Harrison M, Aquilante CL, Sheeder J, Teal S. An exploratory analysis on the influence of genetic variants on weight gain among etonogestrel contraceptive implant users. Contraception. 2020 09; 102(3):180-185.
    View in: PubMed
    Score: 0.005
  50. Leonard CE, Brensinger CM, Dawwas GK, Deo R, Bilker WB, Soprano SE, Dhopeshwarkar N, Flory JH, Bloomgarden ZT, Gagne JJ, Aquilante CL, Kimmel SE, Hennessy S. The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety. Cardiovasc Diabetol. 2020 02 25; 19(1):25.
    View in: PubMed
    Score: 0.005
  51. Lazorwitz A, Aquilante CL, Dindinger E, Harrison M, Sheeder J, Teal S. Relationship Between Etonogestrel Concentrations and Bleeding Patterns in Contraceptive Implant Users. Obstet Gynecol. 2019 10; 134(4):807-813.
    View in: PubMed
    Score: 0.005
  52. Bzowyckyj AS, Aquilante CL, Cheng AL, Drees B. Leveraging the Electronic Medical Record to Identify Predictors of Nonattendance to a Diabetes Self-Management Education and Support Program. Diabetes Educ. 2019 10; 45(5):544-552.
    View in: PubMed
    Score: 0.005
  53. Lazorwitz A, Aquilante CL, Sheeder J, Guiahi M, Teal S. Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users. Contraception. 2019 07; 100(1):37-41.
    View in: PubMed
    Score: 0.005
  54. Lazorwitz A, Aquilante CL, Oreschak K, Sheeder J, Guiahi M, Teal S. Influence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users. Obstet Gynecol. 2019 04; 133(4):783-794.
    View in: PubMed
    Score: 0.005
  55. Leonard CE, Brensinger CM, Aquilante CL, Bilker WB, Boudreau DM, Deo R, Flory JH, Gagne JJ, Mangaali MJ, Hennessy S. Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia. Diabetes Care. 2018 04; 41(4):713-722.
    View in: PubMed
    Score: 0.004
  56. Jurgens PT, Aquilante CL, Page RL, Ambardekar AV. Perioperative Management of Cardiac Transplant Recipients Undergoing Noncardiac Surgery: Unique Challenges Created by Advancements in Care. Semin Cardiothorac Vasc Anesth. 2017 Sep; 21(3):235-244.
    View in: PubMed
    Score: 0.004
  57. Maloney JP, Branchford BR, Brodsky GL, Cosmic MS, Calabrese DW, Aquilante CL, Maloney KW, Gonzalez JR, Zhang W, Moreau KL, Wiggins KL, Smith NL, Broeckel U, Di Paola J. The ENTPD1 promoter polymorphism -860 A > G (rs3814159) is associated with increased gene transcription, protein expression, CD39/NTPDase1 enzymatic activity, and thromboembolism risk. FASEB J. 2017 07; 31(7):2771-2784.
    View in: PubMed
    Score: 0.004
  58. Weitzel KW, Aquilante CL, Johnson S, Kisor DF, Empey PE. Educational strategies to enable expansion of pharmacogenomics-based care. Am J Health Syst Pharm. 2016 Dec 01; 73(23):1986-1998.
    View in: PubMed
    Score: 0.004
  59. Jimmerson LC, Urban TJ, Truesdale A, Baouchi-Mokrane F, Kottilil S, Meissner EG, Sims Z, Langness JA, Hodara A, Aquilante CL, Kiser JJ. Variant Inosine Triphosphatase Phenotypes Are Associated With Increased Ribavirin Triphosphate Levels. J Clin Pharmacol. 2017 01; 57(1):118-124.
    View in: PubMed
    Score: 0.004
  60. Castillo-Mancilla JR, Aquilante CL, Wempe MF, Smeaton LM, Firnhaber C, LaRosa AM, Kumarasamy N, Andrade A, Baheti G, Fletcher CV, Campbell TB, Haas DW, MaWhinney S, Anderson PL. Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342). J Antimicrob Chemother. 2016 06; 71(6):1609-18.
    View in: PubMed
    Score: 0.004
  61. Kiser TH, Fish DN, Aquilante CL, Rower JE, Wempe MF, MacLaren R, Teitelbaum I. Evaluation of sulfobutylether-?-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. Crit Care. 2015 Feb 03; 19:32.
    View in: PubMed
    Score: 0.003
  62. Schoeppler KE, Aquilante CL, Kiser TH, Fish DN, Zamora MR. The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. Clin Transplant. 2014 May; 28(5):590-7.
    View in: PubMed
    Score: 0.003
  63. Beitelshees AL, Aquilante CL, Allayee H, Langaee TY, Welder GJ, Schofield RS, Zineh I. CXCL5 polymorphisms are associated with variable blood pressure in cardiovascular disease-free adults. Hum Genomics. 2012 Aug 02; 6:9.
    View in: PubMed
    Score: 0.003
  64. Kile DA, MaWhinney S, Aquilante CL, Rower JE, Castillo-Mancilla JR, Anderson PL. A population pharmacokinetic-pharmacogenetic analysis of atazanavir. AIDS Res Hum Retroviruses. 2012 Oct; 28(10):1227-34.
    View in: PubMed
    Score: 0.003
  65. Anderson PL, Aquilante CL, Gardner EM, Predhomme J, McDaneld P, Bushman LR, Zheng JH, Ray M, MaWhinney S. Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. J Antimicrob Chemother. 2009 Nov; 64(5):1071-9.
    View in: PubMed
    Score: 0.002
  66. Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr. 2008 Mar 01; 47(3):298-303.
    View in: PubMed
    Score: 0.002
  67. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008 Sep; 84(3):326-31.
    View in: PubMed
    Score: 0.002
  68. Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, Delahunty T, Bushman LR, Fletcher CV. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2008 Feb; 83(2):265-72.
    View in: PubMed
    Score: 0.002
  69. Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr. 2006 Aug 01; 42(4):441-9.
    View in: PubMed
    Score: 0.002
  70. Zineh I, Aquilante CL, Langaee TY, Beitelshees AL, Arant CB, Wessel TR, Schofield RS. CXCL5 gene polymorphisms are related to systemic concentrations and leukocyte production of epithelial neutrophil-activating peptide (ENA-78). Cytokine. 2006 Mar 07; 33(5):258-63.
    View in: PubMed
    Score: 0.002
  71. Zineh I, Pebanco GD, Aquilante CL, Gerhard T, Beitelshees AL, Beasley BN, Hartzema AG. Discordance between availability of pharmacogenetics studies and pharmacogenetics-based prescribing information for the top 200 drugs. Ann Pharmacother. 2006 Apr; 40(4):639-44.
    View in: PubMed
    Score: 0.002
  72. Lin M, Aquilante C, Johnson JA, Wu R. Sequencing drug response with HapMap. Pharmacogenomics J. 2005; 5(3):149-56.
    View in: PubMed
    Score: 0.002
  73. Zineh I, Gerhard T, Aquilante CL, Beitelshees AL, Beasley BN, Hartzema AG. Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs. Pharmacogenomics J. 2004; 4(6):354-8.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)